Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.

Landmark RxPONDER Trial Results

Presented at SABCS 2020

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25

Shaping Clinical Practice: ADAPT and RSClin

Presented at SABCS 2020

Individualized absolute chemotherapy benefit for node-negative breast cancer patients
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.